All clinical trials

Main Trials Page | Search Trials | Clinical Trial Site List | Drug Watch List

First-line Trials | Gleevec/Sutent-resistant | All Trials | Recruiting Trials | Preventative (Adjuvant)Treatment Trials

Click on a column title to sort the list Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

158 trials found Page 1 of 4 | Next | Last

Drug	NCT#	Name	Phase


None	NCT00640692	Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial

Imatinib	NCT00171977	Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)	4

Sunitinib	NCT00793871	Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor (GIST)	4

Imatinib	NCT00009906	Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0033)	3

Imatinib	NCT00041197	Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery	3

Imatinib	NCT00103168	Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor	3

Imatinib	NCT00116935	Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)	3

Imatinib	NCT00293124	Open-Label Trial of Glivec With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors	3

Imatinib	NCT00367861	Prospective Multicentric Randomized Study of Glivec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance	3

Imatinib	NCT00685828	Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor (EORTC-62005)	3

Imatinib	NCT00956072	A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.	3

Imatinib	NCT01031628	Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients	3

Imatinib + Bevacizumab	NCT00324987	Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor	3

IPI-504	NCT00688766	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	3

Masitinib, (AB1010)	NCT00812240	Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour	3

Nilotinib	NCT00471328	Efficacy and Safety of AMN107 Compared Wit h Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	3

Nilotinib	NCT00488150	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	3

Nilotinib or Imatinib	NCT00751036	Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)	3

Nilotinib or Imatinib	NCT00785785	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	3

Sunitinib	NCT00075218	A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumors (Gist)	3

Sunitinib	NCT00085618	SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor	3

Sunitinib	NCT00094029	A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248	3

Sunitinib or Imatinib	NCT00372567	Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg Imatinib)	3

AMG 706	NCT00089960	Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)	2

AMG 706	NCT00254267	Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors (Japan)	2

BIIB021 (CNF2024)	NCT00618319	An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment	2

Dasatinib (BMS-354825)	NCT00568750	Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors	2

Imatinib	NCT00025246	Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery	2

Imatinib	NCT00028002	Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor	2

Imatinib	NCT00112632	Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor	2

Imatinib	NCT00237172	Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) Japan	2

Imatinib	NCT00237185	A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing c-Kit Gene (Extension of US Phase II study)	2

Imatinib	NCT00278876	Adjuvant Imatinib in High-Risk GIST With c-Kit Mutation	2

Imatinib	NCT00290485	Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)	2

Imatinib	NCT00500188	Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST	2

Imatinib	NCT00764595	Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor	2

Imatinib	NCT00867113	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)	2

Imatinib + Oblimersen	NCT00091078	Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery	2

Imatinib + Pegylated Interferon-a 2B	NCT00585221	Study of Imatinib and Pegylated Interferon-a 2B in Imatinib-naïve Gastrointestinal Stromal Tumor (GIST) Patients	2

158 Records found

Page 1 of 4 | Next | Last